

19 November 2008

Med Discovery S.A., a Swiss biotech firm, and Laborium Biopharma, a subsidiary of Validapro Biosciences, have signed a partnership agreement for the development and optimization of protein bioprocess production and scale-up. The first project pursued by the partners is Med Discovery's kallikrein inhibitor MDPK67b, a recombinant therapeutic protein, which regulates different biological pathways involved in prostate cancer. The activity of MDPK67b has been validated in animal models of human prostate tumors.

Under the terms of this agreement, Laborium Biopharma will complete the bacterial production process and scale-up, and produce cGMP clinical material required to perform phase one – two (a) of clinical trials.

Dr. David Deperthes, president and CEO at Med Discovery, commented: "This ambitious project requires a high level of technical expertise and top quality processes that meet the strictest regulatory standards. This collaboration is crucial, as it provides the platform for the development of our early-phase projects. We believe that Laborium Biopharma represents the ideal partner to help us successfully complete this critical phase of our MDPK67b development program."

Luc Dubois, president of Laborium Biopharma, said: "We are very pleased to collaborate with Med Discovery, a bright and innovative company, and are proud of their trust in our capabilities. We will work diligently to help Med Discovery meet the strategic objective of testing its promising therapeutic protein in humans before the end of 2009."

Med Discovery S.A. is a private biopharmaceutical company, headquartered in Geneva, Switzerland, focusing on treatments for uro-genital cancers. The company is dedicated to the discovery and the development of highly specific protein drugs, based on the optimization of natural proteins involved in the

regulation of biological pathways. The company is leveraging a strong in-house expertise combined with an international network in clinical urology.